Ultragenyx Agrees to Sell FDA Priority Review Voucher for $210 Million
Ultragenyx Pharmaceutical entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. The transaction remains subject to customary closing conditions, including expiration of the applicable Hart-Scott-Rodino waiting period.
Why it matters. The sale could provide Ultragenyx with substantial non-dilutive funding for its drug-development programs, while also showing the monetary value of transferable FDA review vouchers.